BIOTECH TARGET N V - 02 Oct 2023 Form 4 Insider Report for MACROGENICS INC (MGNX)

Reporting relationship: 10%+ Owner
Issuer ticker: MGNX
Reported as of: 02 Oct 2023
Net transaction value: +$669,585
SEC form: 4
Accepted by SEC: 04 Oct 2023, 15:31:17 UTC
Prior SEC filing: 11 Sep 2023
Next SEC filing: 04 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Ivo Betschart

Key filing fact

BIOTECH TARGET N V filed Form 4 for MACROGENICS INC (MGNX) on 04 Oct 2023.

Key facts

This page summarizes BIOTECH TARGET N V's Form 4 filing for MACROGENICS INC (MGNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Oct 2023, 15:31.

Change

Previous filing in this sequence was filed on 11 Sep 2023.
Current net transaction value: +$669,585.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MGNX transaction

Common Stock

Purchase

Transaction value: $669,585
Shares: +150,000
Change %: +1.5%
Price: $4.46
Shares after: 9,929,963
Date: 02 Oct 2023
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Macrogenics, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.